Overall, continuous breakthroughs and refinements in PROTAC technology and related TPD strategies offer promise for developing safer, more precise, and controllable ER-targeting therapeutics—potentially transforming the treatment landscape for ERα−positive breast cancer patients. The gene discussed is ESR1; the disease is breast carcinoma.